A Europe where patients get faster and more equitable access to medicines
A more competitive Europe
A more resilient Europe
A Europe where patients get faster and more equitable access to medicines
On average patients in Northern and Western Europe wait between 100 to 350 days to access new medicines. For people living in Southern and Eastern the wait is as long as 600 to 850 days. We believe that for patients, the current system is untenable. To create faster, more equitable access to medicines:
A shared understanding of the root causes of delays and availability of medicines across the EU to improve patients’ access to innovative medicines.
A conversation to explore creating a system where countries with less, pay less for medicines.
A workable system for joint clinical assessment in HTA which includes meaningful involvement of the manufacturer in the process.
A more competitive Europe
Despite our rich legacy, in recent years, Europe has witnessed a gradual decline in its share of global R&D investment, while other, more forward-thinking regions have surged ahead. To regain the ground lost and reduce our reliance on these parts of the world for new diagnostics, treatments and vaccines:
An EU life-science strategy to nurture Europe's innovation ecosystem and achieve EU open strategic autonomy.
A capital markets union to bolster venture capital and mitigate funding risks for biotech endeavors in Europe.
An ambitious reform of the EU regulatory framework
A competitive intellectual property framework to enable investments in the lengthy and risky development of novel treatments.
Multistakeholder collaborations to expedite translation of ideas into tangible health solutions.
A more resilient Europe
The COVID-19 pandemic, wars and natural disasters across the broader European region, and the energy and cost of living crises have hastened fiscal pressure on health systems. Antimicrobial resistance and climate change pose new and urgent threats. To enhance health system sustainability and Europe’s resilience:
A robust pull incentive to enable R&D in novel antibiotics and tackle antimicrobial resistance.
Strengthened prevention and immunisation programmes to reduce the burden of communicable diseases and prepare for future pandemics.
A comprehensive EU approach on chronic and rare diseases to prevent, ensure early and precise diagnosis and reduce the burden of these conditions.
Digitalisation of healthcare delivery and connectivity between healthcare institutions.
Implementation of the EU Green Deal to improve the well-being and health of citizens.